ABSTRACT Systemic antifungal treatments are believed to be more effective than topicals for the treatment of onychomycosis; however, they are associated with more risks of adverse events. Tavaborole is the first member of a new class of antifungals that has been developed as a new topical nail solution for the treatment of toenail onychomycosis caused by dermatophytes. During Phase I-III clinical trials, tavaborole 5.0% nail solution showed a favorable safety and efficacy profile. Tavaborole 5.0% received US FDA market approval on 8 July 2014.
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Guidelines for laser therapy have yet to be published, but several treatment guidelines have been published for the other modes of treatment [11, [17] [18] [19] . Their recommendations are generally based on the safety and efficacy of the interventions as well as the type and the severity of onychomycosis [11, [17] [18] [19] . Indeed, onychomycosis has several clinical presentations classified based on the pattern of nail involvement and extent of invasion [20] . These presentations include distolateral subungual onychomycosis (DLSO), proximal subungual onychomycosis (PSO), superficial onychomycosis (SO) and total dystrophic onychomycosis (TDO), which is the final stage of all patterns of invasion [20] . The general consensus is that systemic antifungals should be used as a first line of therapy with the exception of: cases of SO, when systemic treatments are contraindicated due to medical conditions or risk of drug interactions; and in early cases of DLSO, which can be defined as no matrix involvement, less than 50% nail surface affected and only few digits are infected. In these cases, topical antifungals should be used [11, [17] [18] [19] . Topicals can be combined with nail avulsion or debridement when the presence of dermatophytoma or spikes makes drug penetration suboptimal [11, [17] [18] [19] .
Overview of the market
Several effective systemic therapies are available, but all are associated with risks of adverse events [15] . Topical antifungals are safer than systemic antifungals, but they are less effective [15] . Poor nail permeability and inactivation by keratin are some of the factors limiting the efficacy of current topical antifungals [16, 21] . Several technologies, such as Transfersome ® (IDEA AG, Munich, Germany), are presently being developed to improve nail penetration [16] . Furthermore, the effect of keratin on antifungal activity is now a part of preclinical investigations designed to test prospective antifungals for the treatment of onychomycosis.
Topical antifungals currently used for the treatment of onychomycosis include ciclopirox 8% nail lacquer (available worldwide), amorolfine 5% nail lacquer (unavailable in North America) and efinaconazole 10% nail solution (recently licensed in Canada and the USA) [22, 23] . A Transfersome formulation containing 1.5% of the antifungal terbinafine (TDT-067) underwent Phase II testing and is currently under investigation in a Phase II/III study [24, 25] .
Phase III testing is also in progress regarding luliconazole 10% nail solution [26] . Tavaborole underwent Phase III testing and received US FDA approval on 8 July 2014 [27, 28] .
Introduction to the compound Tavaborole (AN2690), is the first anti fungal benzoxaborole developed by Anacor Pharmaceuticals Inc. for the topical treatment of onychomycosis. Tavaborole is a broad-spectrum antifungal and its activity against the dermatophyte Trichophyton rubrum is not inhibited by nail keratin [29] . Tavaborole has better nail penetration than ciclopirox and amorolfine [29, 30] .
Chemistry
Tavaborole is an antifungal of the oxaborole class of boron-containing compounds ( Figure 1B ) [31] . These compounds were designed from a previous class of borinic acid quinolone ester compounds ( Figure 1A ) with antibacterial properties and they were specifically selected based on their antifungal properties. The broad-spectrum antifungal activity of these compounds was optimized by the addition of a 5-fluoro group and their hydrophilicity optimized by the substitution of a 1-phenyl group for a 1-hydroxy group ( Figure 1C) . This optimal compound, 1-hydroxy-5-fluoro-1,3-dihydro-2,1benzoxaborole has also been shown to maintain its activity in presence of keratin [29] and to have better in vitro nail penetration than other oxaboroles at a 10% concentration in ethanol and ciclopirox 8% nail lacquer [30] . This compound, AN2690, was selected for future drug development for the topical treatment of onychomycosis and was subsequently named tavaborole.
Further studies using normal human nails from cadavers were performed to adjust the tavaborole 10% formulation to achieve optimal nail penetration [30] . Nail penetration was tested with four different formulations [30] . Three of these formulations were nail lacquers: 70% ethanol, 20% poly (vinyl methyl ether alt maleic acid monobutyl ester) producing a durable water insoluble film, 56% ethanol, 14% water, 15% poly (2-hydroxyethyl methacrylate) 5% dibutyl sebacate producing a less durable water soluble film and 55% ethanol, 15% ethyl acetate, 15% poly (vinyl acetate), and 5% dibutyl sebacate producing a less durable water insoluble film, which can be peeled off [30] . The last formulation was a simple solvent vehicle, 20% propylene glycol, 70% ethanol [30] . There future science group www.futuremedicine.com were no statistically significant differences in nail penetration between these formulations; thus, the simple solvent vehicle was selected for further comparison with ciclopirox 8% nail lacquer. The weight-normalized concentration of tavaborole in all parts of the nail was significantly higher (p ≤ 0.002) than the weightnormalized concentration of ciclopirox after a 14-day treatment.
Pharmacodynamics
Among all of the antifungal treatments for onychomycosis, the mechanism of action of tavaborole is unique. Indeed, the three systemic antifungals usually prescribed (terbinafine, itraconazole and fluconazole) and two of the approved topical antifungals (efinaconazole and amorolfine) inhibit the synthesis of ergosterol, an important component of the fungal cell membrane required for membrane integrity and fungal growth, whereas the other approved topical antifungal (ciclopirox) impairs microbial metabolism [32, 33] . The novel antifungal properties of tavaborole are due to its specific targeting of an enzyme involved in fungal protein synthesis in [34, 35] . Indeed, protein synthesis requires the involvement of a family of enzymes called aminoacyl-tRNA synthetases [34, 35] . These enzymes catalyze the specific attachment of amino acids to their tRNAs [34, 35] . As similar amino acids can be mistakenly charged, these enzymes evolved to include an editing site for the recognition and release of these mischarged amino acids [34, 35] . Tavaborole forms, via its boron atom, a covalent adduct with the tRNA for leucine within the editing site of the LeuRS [34, 35] . The enzyme is then locked in an inactive form, which results in the interruption of protein synthesis [34, 35] . Based on the analysis of crystal structures, small differences between the editing domain of the human and fungal LeuRS contribute to the fungal specificity of this mechanism of action [35] .
Pharmacokinetics & metabolism
To determine the extent of systemic exposure, topical tavaborole 7.5% solution was applied daily for 28 days to all toenails of 15 participants with moderate to severe onychomycosis [36] . The daily volume applied was at least 0.25 ml of solution. Two sets of blood samples were collected. The first set was collected before participants received a dose at 0, 1, 14, 15 and 28 days. The second set was collected 0.25, 0.5, 1, 2, 3, 4, 6 and 8 h after receiving a dose on days 0, 14 and 28. The level of tavaborole was under the detectable level (25 ng/ml) in all samples [36] .
Accumulation in the toenail was also assessed during and after application of tavaborole 7.5% solution once daily for 28 days in a Phase I clinical trial with 15 participants with moderate to severe toenail onychomycosis [37] . In these participants with a combined thickness of the nail plate and the nail bed >3 mm, a concentration of 29 μg of tavaborole per mg of nail was achieved after 28 days [37] . This concentration corresponds to about 5000-times the MIC 90 and 600-times the minimum fungicidal concentration (MFC) of tavaborole for T. rubrum. 5 months after the last dose, tavaborole was still detected at a concentration of 0.10 μg/mg, which corresponds to 17-times the minimum inhibitory concentration to erradicate 90% of the infection (MIC 90 ) and twice the MFC for T. rubrum [37] . Thus, high levels of tavaborole are achieved in the toenail following daily application and tavaborole remains in the toenail for an extended period of time. An open-label multidose study examined 15 participants with onychomycosis affecting at least 80% of both great toenails and a combined thickness of the nail plate and nail bed of >3 mm for each great toenail [36] . Participants were potassium hydroxide (KOH) positive for onychomycosis of at least one great toenail and must have had a clinical diagnosis of onychomycosis in at least In a nonrandomized open-label study (Phase II 201), 89 participants were recruited in three arms (Table 2 ) [40] . Participants in the two parallel arms (Cohorts 1 and 2) were required to have DLSO (confirmed by KOH) affecting 20-60% of the great toenail with demonstrated nail growth capability. Participants in these arms were treated once daily for 6 months with tavaborole 5.0 or 7.5% solution. While in the third arm (Cohort 3), participants were required to have DLSO confirmed by KOH and culture affecting 20-60% of the great toenail and demonstrated nail growth capability and these participants were treated once daily for 12 months with tavaborole 5.0% solution. The efficacy outcome was defined as negative culture and at least 2 mm of clear nail Table 1 . Minimum inhibitory concentration of tavaborole, amorolfine and efinaconazole compared with ciclopirox.
Infectious organism
Minimum inhibitory concentration (μg/ml) Ref.
Tavaborole

Ciclopirox Amorolfine Efinaconazole Dermatophytes
Trichophyton rubrum 1-8 0.03-1 0.004-0.015 0.001-0.015 [29, 38] Trichophyton mentagrophytes 2-8 0.03-0.5 0.004-0.06 0.001-0.03 [29, 38] Trichophyton tonsurans 2-4 ≤0.5 0.25 0.016 [29, 38] Epidermophyton floccosum ≤0.5 0.25-0.5 0.13-0.25 ≤0.002-0.0078 [29, 38] Microsporum audouinii 2 1 -- [29] Microsporum canis 2 0.25-0.5 >4 0.13-0.25 [29, 38] Microsporum gypseum 2 0.25-0.5 0.063-0.13 0.0039-0.016 [29, 38] 
Nondermatophyte molds
Aspergillus fumigutus 0.25 0.25-0.50 >4 0.031-0.5 [29, 38] Fusarium solani ≤0.5 ≥4 >4 0.5 [29, 38] Yeasts Candida albicans 1.0 0.06-0.5 ≤0.03-8 ≤0.0005->0.25 [29, 38] Candida glabrata ≤0.5 0.13-0.5 2->8 0.0039-0.13 [29, 38] Candida krusei 1 0.13-0.25 0.13-0.5 0.0078-0.063 [29, 38] Candida parapsilosis ≤0.5 0.13-0.5 0.13-4 <0.002-0.016 [29, 38] Candida tropicalis ≤0.5 ≤0.5 ≤0.016->8 0.0078-0.063 [29, 38] Cryptococcus neoformans 0.25 ≤0.031 ≤0.016-0.13 0.002-0.0039
Malassezia furfur 1 ≤0.5 -- [29] Malassezia pachydermatis 1 ≤0.5 -- [29] Malassezia sympodialis 1 ≤0.5 -- [29] future science group www.futuremedicine.com Ref.
[ In a final multicenter open-label Phase II study, two additional dosing regimens were evaluated in 60 participants with similar inclusion criteria as the double-blind study (Table 2 ) [40] . The first 30 participants were assigned to the first treatment arm where tavaborole 1.0% solution was applied once daily for 6 months. The next 30 participants were assigned to the second treatment arm where tavaborole 5.0% solution was applied once daily for the first month and then three-times weekly for the following 5 months. The efficacy outcome was the rate of participants achieving negative culture and at least 2 mm of clear nail growth or an ISGA of clear or almost clear. After 6 months of treatment, the tavaborole 1.0% arm achieved a 30% success rate and the tavaborole 5.0% arm achieved a 50% success rate (Table 2) [40].
• • Phase III studies Two identical randomized, double-blind, vehicle-controlled Phase III studies were performed in Mexico, Canada and the USA [45] . Adult participants aged 18 and older with KOH and culture-confirmed DLSO of one great toenail (20-60% nail surface involvement), a clear proximal nail of 3 mm or more, and a distal nail thickness of 3 mm or less were randomized 2:1 to tavaborole 5.0% nail solution or vehicle. Debridement or aggressive nail trimming was not permitted (defined as no more than 1 mm from the hyponychium). The first trial (Study 301) included 593 participants in the USA and Mexico, and the second trial (Study 302) included 604 participants in the USA and Canada. Tavaborole 5.0% solution or vehicle was applied once daily for 48 weeks. The primary efficacy end point was complete cure of the target great toenail defined as a completely clear nail and negative mycology (KOH and culture) at week 52. Secondary end points included clinical cure (completely clear or almost clear target nail) and mycological cure. In both Studies 301 and 302, participants in the tavaborole group had significantly higher rates of complete, clinical and mycological cure compared with participants who received vehicle (p ≤ 0.001) ( Tavaborole was tested against five cytochrome P450 isoforms: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. At a concentration of 10 μM, tavaborole did not significantly inhibit any of these enzymes [47] . These data combined with the negligible systemic absorption of topically applied tavaborole suggest that there is little risk of drug-drug interactions associated with this intervention.
In vitro and in vivo animal experiments demonstrated that there was no genetic toxicity associated with tavaborole [48] . Tavaborole 10% solution and its vehicle were not primary irritants or contact sensitizers. Local skin irritation was observed in mini pigs after daily application in a dose-dependent manner [47, 49] . Moreover, eye irritation likely due to the vehicle was observed in rabbits [47] . Thus, contact with the eyes should be avoided. Reduced fetal body weight was observed in rabbits following topical application of tavaborole 10% solution, but not with the tavaborole 5% solution used in the Phase III studies [49] .
•
• Clinical studies
The safety information released for the Phase III studies reports that none of the serious adverse events were related to tavaborole and that the treatment with tavaborole 5% solution was associated with a low rate of discontinuation due to adverse events (0.8-2.9 vs 0.5-1.5% for vehicle). The treatment-related adverse events observed included the following application site reactions: exfoliation (2.7%), erythema (1.6%) and dermatitis (1.3%) [45] . Mild to moderate, reversible application site reactions were also reported as the most common adverse events in Phase II studies [38, 40, 50] . In the Phase I study conducted using tavaborole 7.5% solution, no laboratory abnormalities were observed for routine hematology and serum chemistry [36] . Taken together, these data show that tavaborole 5.0% solution is a safe topical treatment for onychomycosis.
Regulatory affairs
Tavaborole received FDA approval on 8 July 2014 [28] .
Conclusion
Tavaborole is a safe topical treatment for onychomycosis with a novel mechanism of action. Its efficacy for mild to moderate toenail DLSO caused by dermatophytes is comparable to other approved topical antifungals. It is also worth noting that Anacor Pharmaceuticals Inc. is currently developing a second benzoxaborole compound, AN2718, for the treatment of skin and nail fungal infections [51] . 
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EXECUTIVE SUMMARY
Mechanisms of action
• Tavaborole is a boron-containing antifungal targeting the fungal LeuRS enzyme involved in the protein synthesis.
Pharmacokinetic properties
• The level of systemic tavaborole is not detectable after daily topical application of a 7.5% solution over 28 days.
• Tavaborole accumulates in the toenail at a concentration superior to its minimum inhibitory concentration and is still detectable several months after its application.
Clinical efficacy
• Tavaborole is more efficacious than vehicle for the treatment of toenail distolateral subungual oncyhomycosis caused by dermatophytes.
• No clinical trials have been performed for onychomycosis caused by Candida spp.
Safety & tolerability
• Preclinical and clinical data suggest that tavaborole is a safe topical treatment for onychomycosis.
Drug interactions
• Tavaborole does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
• Topically applied tavaborole has negligible systemic absorption.
Dosage & administration
• In Phase III studies, tavaborole 5.0% nail solution was applied once daily for 48 weeks.
